Ralph Z. Kern
Net Worth

Last updated:

What is Ralph Z. Kern net worth?

The estimated net worth of Dr. Ralph Z. Kern is at least $5,984,716 as of 24 Dec 2019. He owns shares worth $75,176 as insider and has received compensation worth at least $5,909,540 in Brainstorm Cell Therapeutics Inc..

What is the salary of Ralph Z. Kern?

Dr. Ralph Z. Kern salary is $844,220 per year as Pres & Chief Medical Officer in Brainstorm Cell Therapeutics Inc..

How old is Ralph Z. Kern?

Dr. Ralph Z. Kern is 67 years old, born in 1958.

What stocks does Ralph Z. Kern currently own?

As insider, Dr. Ralph Z. Kern owns shares in one company:

Company Title Shares Price per share Total value
Brainstorm Cell Therapeutics Inc. (BCLI) Pres & Chief Medical Officer 115,655 $0.65 $75,176

What does Brainstorm Cell Therapeutics Inc. do?

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Ralph Z. Kern insider trading

Brainstorm Cell Therapeutics Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 3,000 $3.88 $11,640
Purchase
Common Stock 5,000 $3.6 $17,995

Brainstorm Cell Therapeutics key executives

Brainstorm Cell Therapeutics Inc. executives and other stock owners filed with the SEC: